These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 17868339)

  • 21. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Iyer RB; Zhou Q; Iasonos A; Denesopolis J; Zivanovic O; Long Roche KC; Sonoda Y; Coleman RL; Abu-Rustum NR; Hricak H; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):27-31. PubMed ID: 28209497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy.
    Bland AE; Everett EN; Pastore LM; Andersen WA; Taylor PT
    Int J Gynecol Cancer; 2008; 18(4):629-36. PubMed ID: 17986246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
    Angioli R; Capriglione S; Aloisi A; Ricciardi R; Scaletta G; Lopez S; Miranda A; Di Pinto A; Terranova C; Plotti F
    Ann Surg Oncol; 2015 Dec; 22(13):4217-23. PubMed ID: 25808099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
    Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
    Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?
    Mousavi AS; Mazhari MM; Guilani MM; Ghaemmaghami F; Behtash N; Akhavan S
    World J Surg Oncol; 2010 Feb; 8():11. PubMed ID: 20170515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?
    Angioli R; Plotti F; Capriglione S; Aloisi A; Montera R; Luvero D; Miranda A; Cafà EV; Damiani P; Benedetti-Panici P
    Gynecol Oncol; 2013 Mar; 128(3):579-83. PubMed ID: 23220563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
    Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
    Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
    Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer.
    Petri AL; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Høgdall CK
    APMIS; 2006 May; 114(5):359-63. PubMed ID: 16725012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
    Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
    Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer.
    Everett EN; Heuser CC; Pastore LM; Anderson WA; Rice LW; Irvin WP; Taylor PT
    Am J Obstet Gynecol; 2005 Aug; 193(2):568-74; discussion 574-6. PubMed ID: 16098898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?
    Saygili U; Guclu S; Uslu T; Erten O; Demir N; Onvural A
    Gynecol Oncol; 2002 Jul; 86(1):57-61. PubMed ID: 12079301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.